TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2022 Dec 23

PMID 36558936

Authors

Cheol Ho Park

Tae-Hyun Yoo

Affiliations

Soon will be listed here.

Abstract

Kidney fibrosis is a common pathophysiological mechanism of chronic kidney disease (CKD) progression caused by several underlying kidney diseases. Among various contributors to kidney fibrosis, transforming growth factor-β1 (TGF-β1) is the major factor driving fibrosis. TGF-β1 exerts its profibrotic attributes via the activation of canonical and non-canonical signaling pathways, which induce proliferation and activation of myofibroblasts and subsequent accumulation of extracellular matrix. Over the past few decades, studies have determined the TGF-β1 signaling pathway inhibitors and evaluated whether they could ameliorate the progression of CKD by hindering kidney fibrosis. However, therapeutic strategies that block TGF-β1 signaling have usually demonstrated unsatisfactory results. Herein, we discuss the therapeutic concepts of the TGF-β1 signaling pathway and its inhibitors and review the current state of the art regarding regarding TGF-β1 inhibitors in CKD management.

Citing Articles

Dapagliflozin inhibits ferroptosis and ameliorates renal fibrosis in diabetic C57BL/6J mice.

Zhang Z, Li L, Dai Y, Lian Y, Song H, Dai X Sci Rep. 2025; 15(1):7117.

PMID: 40016517 PMC: 11868513. DOI: 10.1038/s41598-025-91278-4.

Renal dysplasia development and chronic kidney disease.

Zhang L, Yang C, Liu X, He D, Lin T, Zhang Y Pediatr Res. 2025; .

PMID: 40000855 DOI: 10.1038/s41390-025-03950-0.

Interrelation of Natural Polyphenol and Fibrosis in Diabetic Nephropathy.

Ma Y, Wang J, Fan J, Jia H, Li J Molecules. 2025; 30(1).

PMID: 39795078 PMC: 11722366. DOI: 10.3390/molecules30010020.

BK Polyomavirus and acute kidney injury in transplant recipients: signaling pathways and molecular mechanisms.

Bizhani S, Afshari A, Yaghobi R Virol J. 2025; 22(1):2.

PMID: 39755619 PMC: 11700467. DOI: 10.1186/s12985-024-02620-7.

Integrins as Drug Targets in Vascular and Related Diseases.

Meredith E, Schwartz M Int J Drug Discov Pharm. 2024; 3(2).

PMID: 39703402 PMC: 11658063. DOI: 10.53941/ijddp.2024.100010.

References

Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

Bohle A, Grund K, Mackensen S, Tolon M . Correlations between renal interstitium and level of serum creatinine. Morphometric investigations of biopsies in perimembranous glomerulonephritis. Virchows Arch A Pathol Anat Histol. 1977; 373(1):15-22. DOI: 10.1007/BF00432465. View

Magin M, Delling G . Improved lumbar vertebral interbody fusion using rhOP-1: a comparison of autogenous bone graft, bovine hydroxylapatite (Bio-Oss), and BMP-7 (rhOP-1) in sheep. Spine (Phila Pa 1976). 2001; 26(5):469-78. DOI: 10.1097/00007632-200103010-00009. View

Hinck A . Structural studies of the TGF-βs and their receptors - insights into evolution of the TGF-β superfamily. FEBS Lett. 2012; 586(14):1860-70. DOI: 10.1016/j.febslet.2012.05.028. View

Souchelnytskyi S, Tamaki K, Engstrom U, Wernstedt C, Ten Dijke P, Heldin C . Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J Biol Chem. 1997; 272(44):28107-15. DOI: 10.1074/jbc.272.44.28107. View

Ten Dijke P, Arthur H . Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007; 8(11):857-69. DOI: 10.1038/nrm2262. View

Zhang Y, Meng X, Huang X, Lan H . The preventive and therapeutic implication for renal fibrosis by targetting TGF-β/Smad3 signaling. Clin Sci (Lond). 2018; 132(13):1403-1415. DOI: 10.1042/CS20180243. View

Li R, Yiu W, Tang S . Role of bone morphogenetic protein-7 in renal fibrosis. Front Physiol. 2015; 6:114. PMC: 4407503. DOI: 10.3389/fphys.2015.00114. View

Kretzschmar M, Doody J, Timokhina I, Massague J . A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev. 1999; 13(7):804-16. PMC: 316599. DOI: 10.1101/gad.13.7.804. View

10.

Garber K . Companies waver in efforts to target transforming growth factor beta in cancer. J Natl Cancer Inst. 2009; 101(24):1664-7. DOI: 10.1093/jnci/djp462. View

11.

Schiffer M, Bitzer M, Roberts I, Kopp J, Ten Dijke P, Mundel P . Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest. 2001; 108(6):807-16. PMC: 200928. DOI: 10.1172/JCI12367. View

12.

Lee M, Pardoux C, Hall M, Lee P, Warburton D, Qing J . TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 2007; 26(17):3957-67. PMC: 1994119. DOI: 10.1038/sj.emboj.7601818. View

13.

Williams K, Qiu G, Usui H, Dunn S, McCue P, Bottinger E . Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol. 2007; 171(5):1441-50. PMC: 2043506. DOI: 10.2353/ajpath.2007.070079. View

14.

Zeisberg M, Bottiglio C, Kumar N, Maeshima Y, Strutz F, Muller G . Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol. 2003; 285(6):F1060-7. DOI: 10.1152/ajprenal.00191.2002. View

15.

Veerasamy M, Nguyen T, Motazed R, Pearson A, Goldschmeding R, Dockrell M . Differential regulation of E-cadherin and alpha-smooth muscle actin by BMP 7 in human renal proximal tubule epithelial cells and its implication in renal fibrosis. Am J Physiol Renal Physiol. 2009; 297(5):F1238-48. DOI: 10.1152/ajprenal.90539.2008. View

16.

Border W, Noble N, Yamamoto T, Harper J, Yamaguchi Y, Pierschbacher M . Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature. 1992; 360(6402):361-4. DOI: 10.1038/360361a0. View

17.

Li M, Flavell R . TGF-beta: a master of all T cell trades. Cell. 2008; 134(3):392-404. PMC: 3677783. DOI: 10.1016/j.cell.2008.07.025. View

18.

Zhao S, Li W, Yu W, Rao T, Li H, Ruan Y . Exosomal miR-21 from tubular cells contributes to renal fibrosis by activating fibroblasts via targeting PTEN in obstructed kidneys. Theranostics. 2021; 11(18):8660-8673. PMC: 8419054. DOI: 10.7150/thno.62820. View

19.

Bottinger E, Bitzer M . TGF-beta signaling in renal disease. J Am Soc Nephrol. 2002; 13(10):2600-10. DOI: 10.1097/01.asn.0000033611.79556.ae. View

20.

Chung A, Lan H . MicroRNAs in renal fibrosis. Front Physiol. 2015; 6:50. PMC: 4335396. DOI: 10.3389/fphys.2015.00050. View